MBX, Zenas and Bicara delivered positive returns in their first days of trading, but that has not always translated to good long-term results for drug developers that launched US IPOs this year.

The Democratic Republic of Congo, the country worst hit by the mpox crisis, has now received the first batch of vaccines for the disease. Meanwhile, the World Health Organization is expected to complete its review for emergency use listing of mpox vaccines soon.

Manufacturer KM Biologics has confirmed to the Pink Sheet it has filed for an emergency use listing to WHO for its mpox vaccine LC16, which has shown efficacy for post-exposure prophylaxis within 14 days, although its efficacy for pre-exposure prophylaxis is still inconclusive.

Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.